Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody–Drug Conjugates with Self-Immolative Disulfide Linkers
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
A novel disulfide linker was designed to enable a direct connection between cytotoxic pyrrolobenzodiazepine (PBD) drugs and the cysteine on a targeting antibody for use in antibody–drug conjugates (ADCs). ADCs composed of a cysteine-engineered antibody were armed with a PBD using a self-immolative disulfide linker. Both the chemical linker and the antibody site were optimized for this new bioconjugation strategy to provide a highly stable and efficacious ADC. This novel disulfide ADC was compared with a conjugate containing the same PBD drug, but attached to the antibody via a peptide linker. Both ADCs had similar efficacy in mice bearing human tumor xenografts. Safety studies in rats revealed that the disulfide-linked ADC had a higher MTD than the peptide-linked ADC. Overall, these data suggest that the novel self-immolative disulfide linker represents a valuable way to construct ADCs with equivalent efficacy and improved safety. Mol Cancer Ther; 16(5); 871–8. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Minor groove binder antibody conjugates employing a water soluble β-glucuronide linker
Jeffrey, S. C., Nguyen, M. T., Moser, R. F., Meyer, D. L., Miyamoto, J. B., & Senter, P. D. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.01.071 · Cited by 59
Cited by
Cleavable linkers in antibody–drug conjugates
Bargh, J. D., Isidro-Llobet, A., Parker, J. S., & Spring, D. R. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00676h · Cited by 652
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
Antibody–drug conjugates: Recent advances in linker chemistry
Su, Z., Xiao, D., Xie, F., Liu, L., Wang, Y., Fan, S., Zhou, X., & Li, S. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.042 · Cited by 403
Self-citationPotential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates
Mahalingaiah, P. K., Ciurlionis, R., Durbin, K. R., Yeager, R. L., Philip, B. K., Bawa, B., Mantena, S. R., Enright, B. P., Liguori, M. J., & Van Vleet, T. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.008 · Cited by 286
Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity
Pillow, T. H., Adhikari, P., Blake, R. A., Chen, J., Del Rosario, G., Deshmukh, G., Figueroa, I., Gascoigne, K. E., Kamath, A. V., Kaufman, S., et al. (2020) · ChemMedChem · doi:10.1002/cmdc.201900497 · Cited by 216
Self-citation
Metadata
- Authors
- Pillow, T. H., Schutten, M., Yu, S.-F., Ohri, R., Sadowsky, J., Poon, K. A., Solis, W., Zhong, F., Del Rosario, G., Go, M. A. T., Lau, J., Yee, S., He, J., Liu, L., Ng, C., Xu, K., Leipold, D. D., Kamath, A. V., Zhang, D., Masterson, L., Gregson, S. J., Howard, P. W., Fang, F., Chen, J., Gunzner-Toste, J., Kozak, K. K., Spencer, S., Polakis, P., Polson, A. G., Flygare, J. A., & Junutula, J. R.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2017-05-01
- Volume
- 16
- Issue
- 5
- Pages
- 871-878
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2591098696
- Cited by
- 72
- References
- 1
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody–Drug Conjugates with Self-Immolative Disulfide Linkers. https://app.cochat.ai/papers/10.1158/1535-7163.mct-16-0641
- The paper
- Pillow, T. H., Schutten, M., Yu, S.-F., Ohri, R., Sadowsky, J., Poon, K. A., Solis, W., Zhong, F., Del Rosario, G., Go, M. A. T., Lau, J., Yee, S., He, J., Liu, L., Ng, C., Xu, K., Leipold, D. D., Kamath, A. V., Zhang, D., . . . Junutula, J. R. (2017). Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody–Drug Conjugates with Self-Immolative Disulfide Linkers. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-16-0641
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.